102.49 USD
↘ 2.28 (2.18%)AT CLOSE (11:59 AM EDT)
Dianthus Therapeutics, Inc. Common Stock
DNTHNASDAQ • USD
102.62
↗ 0.13 (0.12%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
102.62
↗ 0.13 (0.12%)
Market: CLOSED
Dianthus Therapeutics, Inc. Common Stock (DNTH) trades at $102.48 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 16, 2026.
Open?$105.43
High?$107.00
Low?$101.60
Prev. Close?$104.77
Volume?1.0M
Avg. Volume?631.2K
VWAP?$103.30
Rel. Volume?1.64x
Bid / Ask
Bid?$89.25 × 100
Ask?$117.53 × 100
Spread?$28.28
Midpoint?$103.39
Valuation & Ratios
Market Cap?5.9B
Shares Out?54.7M
Float?51.2M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?5.00
EPS?-$3.44
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Employees
92
Market Cap
5.9B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055
NEW YORK, NY 10036
Phone: 929-999-4055
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?100
Momentum?48
Short Sent.?39
Piotroski F-Score?2/9Weak
Altman Z-Score?85.02Safe
Confidence?55%Low
Short InterestVery High
Short % of Float?16.46%High
Short Interest?8.4M
Days to Cover?15.3
Free Float51.2M
Avg Daily Volume550.8K
Settlement Date2026-08-31
Financial Health
Current Ratio?26.10Strong
Quick Ratio?26.10Strong
Cash Ratio?3.21Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.00FAIR▾
Peers100
S&P37
P/S?3,077.86HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-26.4CHEAP▾
S&P97
EV/Sales?3,019.80HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-16.4%WEAK▾
S&P8
ROA?-15.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-155709000
Enterprise Value?$5.7B
Fundamentals ratios updated end of day